Learning Objectives: -Incorporate clinical evidence on CDK4/6 inhibitor-containing adjuvant therapy into treatment plans for patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) -Develop supportive approaches to proactively monitor and mitigate adverse events (AEs) associated with CDK4/6 inhibitor-containing regimens in patients with HR+, HER2- EBC -Implement multidisciplinary strategies to improve patient adherence and persistence to adjuvant CDK4/6 inhibitor therapies, including patient-centered nursing approaches
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 40946 US Highway 19 N
Pricing
CME included with membership · $19.99/mo
| Regular Membership | Free |
| Affiliated Health Professional Membership | Free |
| MENASA Group Explorer | Free |
| MENASA Group Elite Member | $19.99/mo |
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuroradiology
- Ophthalmology
- Patient Education & Health Literacy
- Pediatric Gastroenterology
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Thoracic Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedMay 20, 2026
-
Last day to claim creditMay 20, 2027 7 months left
-
American Society of Clinical Oncology Breast Cancer Local/Regional/Adjuvant (Oral Abstract Session) – 2026 ASCO Annual Meeting
-
Learner’s Digest International (TM) Using ctDNA to Drive Decision Making in Adjuvant Chemotherapy for Colon Cancer
-
Partners for Advancing Clinical Education Fundamentals I: Optimizing Adjuvant Therapy in Patients With High-Risk HR+/HER2- EBC
-
Medical Learning Institute, Inc. Nursing Voices from the Frontline: Adjuvant CDK4/6 Therapy in HR+ HER2- Breast Cancer
-
Medical Learning Institute, Inc. Expert Exchanges on the Evolving Treatment Landscape of Acute Lymphoblastic Leukemia
-
Medical Learning Institute, Inc. NSCLC Game Plan: Navigating HER2 with Evidence and Insight
